The robust growth was driven by expanded use in both early and advanced breast cancer settings, particularly following its approval for adjuvant treatment in high-risk early-stage patients
Perfil: Transportador, oxidorreductor de grasa, anticelultico cosmtico y dinamizador
Evidence suggests mixed outcomes depending on treatment duration and individual skin factors
Semaglutide (marketed as Wegovy, for instance) is approved for treating obesity in non-diabetic adults and has also shown strong results
1 Endocrinology and Metabolism, Harvard Medical School, Boston, MA, USA, 2 University of Washington, Seattle, WA, USA, 3 New York Academy of Medicine, New York City, NY, USA, 4 Kaiser Permanente of Georgia, Duluth, GA, USA, 5 Endocrinology and Metabolism, University of Toronto, Toronto, ON, Canada, 6 Harvard Medical School, Boston, MA, USA, 7 University of California San Diego, San Diego, CA, USA, 8 University of California San Francisco, San Francisco, CA, USA
Patient Preference and Tolerance: Side effects and administration method (injection) are considered